Different studies from different institution indicated the same finding that HER2 overexpression is correlated with HR negativity, while the relationship between HER2 expression and other clinicopathologic parameters varies, such as tumor dimension, nodal involvement and tumor grading. This evidence concerns the gene ERBB2 and neoplasm.